Market Price

8.20 

0.00 0.0%

as of Sep 23 '22

52 Week Range:

7.60 17.40


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Equity (BVPS) 9.66
8.74
9.85
9.48
10.48
10.66
12.17
11.33
12.10
12.48
growth rate -9.5% 12.7% -3.8% 10.6% 1.7% 14.2% -6.9% 6.8% 3.1%
Earnings BIT 150.24
25,044.00
42,143.00
23,276.00
36,930.00
52,759.00
82,718.00
61,272.00
82,922.00
54,299.00
59,967.00
growth rate 16,569.8% 68.3% -44.8% 58.7% 42.9% 56.8% -25.9% 35.3% -34.5% 10.4%
Avg.PE 40.32
66.67
32.89
35.44
21.38
25.30
15.59
31.57
31.57
31.57
6.36
growth rate 65.4% -50.7% 7.8% -39.7% 18.3% -38.4% 102.5% 0.0% 0.0% -79.9%
ROA 1.50
1.72
3.17
2.25
3.48
3.86
6.67
5.91
3.90
4.39
growth rate 14.7% 84.3% -29.0% 54.7% 10.9% 72.8% -11.4% -34.0% 12.6%
ROE 2.68
3.00
5.37
3.64
5.50
6.39
11.70
10.23
7.93
10.13
growth rate 11.9% 79.0% -32.2% 51.1% 16.2% 83.1% -12.6% -22.5% 27.7%
ROIC 1.99
2.32
4.30
3.07
4.81
5.64
10.80
8.41
5.94
6.14
growth rate 16.6% 85.3% -28.6% 56.7% 17.3% 91.5% -22.1% -29.4% 3.4%
Cur. Ratio 3.15
2.67
2.74
2.56
2.35
1.65
1.65
1.88
0.73
1.65
growth rate -15.2% 2.6% -6.6% -8.2% -29.8% 0.0% 13.9% -61.2% 126.0%
Quick Ratio 2.26
1.90
1.97
1.87
1.62
1.02
1.35
1.51
0.53
1.29
growth rate -15.9% 3.7% -5.1% -13.4% -37.0% 32.4% 11.9% -64.9% 143.4%
Leverage 1.75
1.74
1.65
1.58
1.59
1.72
1.79
1.68
2.37
2.25
growth rate -0.6% -5.2% -4.2% 0.6% 8.2% 4.1% -6.2% 41.1% -5.1%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 101,845.00
132,459.00
154,170.00
151,999.00
155,587.00
127,659.00
113,401.00
119,243.00
140,368.00
136,060.00
151,500.00
growth rate 30.1% 16.4% -1.4% 2.4% -18.0% -11.2% 5.2% 17.7% -3.1% 11.4%
Acct.Payable 46,812.00
43,884.00
12,492.00
12,153.00
14,514.00
58,708.00
49,238.00
62,251.00
64,638.00
46,183.00
growth rate -6.3% -71.5% -2.7% 19.4% 304.5% -16.1% 26.4% 3.8% -28.6%
Cur.Assets 334,250.00
333,439.00
359,612.00
401,699.00
421,584.00
376,454.00
348,581.00
373,268.00
364,090.00
459,795.00
499,521.00
growth rate -0.2% 7.9% 11.7% 5.0% -10.7% -7.4% 7.1% -2.5% 26.3% 8.6%
Total Assets 5,146.57
607,219.00
659,033.00
711,583.00
707,715.00
793,950.00
809,684.00
834,717.00
1,252,878.00
1,308,127.00
1,308,007.00
growth rate 11,698.5% 8.5% 8.0% -0.5% 12.2% 2.0% 3.1% 50.1% 4.4% 0.0%
Cash 119.17
12,601.00
22,299.00
30,553.00
54,922.00
71,408.00
147,775.00
137,296.00
101,708.00
193,698.00
202,984.00
growth rate 10,474.2% 77.0% 37.0% 79.8% 30.0% 106.9% -7.1% -25.9% 90.5% 4.8%
Inventory 58,116.00
62,689.00
59,143.00
62,387.00
59,587.00
68,806.00
60,169.00
66,889.00
79,368.00
92,215.00
99,021.00
growth rate 7.9% -5.7% 5.5% -4.5% 15.5% -12.6% 11.2% 18.7% 16.2% 7.4%
Cur.Liabilities 105,965.00
124,831.00
131,208.00
156,843.00
179,722.00
228,447.00
210,248.00
198,174.00
496,498.00
278,147.00
278,373.00
growth rate 17.8% 5.1% 19.5% 14.6% 27.1% -8.0% -5.7% 150.5% -44.0% 0.1%
Liabilities 2,209.67
257,971.00
260,493.00
260,562.00
261,243.00
333,294.00
356,961.00
336,579.00
620,773.00
659,949.00
634,438.00
growth rate 11,574.6% 1.0% 0.0% 0.3% 27.6% 7.1% -5.7% 84.4% 6.3% -3.9%
LT Debt 1,085.60
95,000.00
85,000.00
50,000.00
28,000.00
10,000.00
30,940.00
27,980.00
25,020.00
263,859.00
243,963.00
growth rate 8,650.9% -10.5% -41.2% -44.0% -64.3% 209.4% -9.6% -10.6% 954.6% -7.5%
Equity 2,936.89
3,213.08
398,540.00
451,021.00
446,472.00
460,656.00
452,723.00
498,138.00
529,485.00
580,570.00
607,888.00
growth rate 9.4% 12,303.7% 13.2% -1.0% 3.2% -1.7% 10.0% 6.3% 9.7% 4.7%
Common Shares 397.00
397.00
397.00
397.00
397.00
397.00
22,400.00
22,400.00
22,400.00
22,400.00
22,400.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 5,542.3% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 43.89
7,818.00
10,332.00
8,662.00
5,382.00
8,132.00
5,129.00
9,265.00
7,722.00
6,048.00
7,347.00
growth rate 17,711.4% 32.2% -16.2% -37.9% 51.1% -36.9% 80.6% -16.7% -21.7% 21.5%
Cash Dividends 65.77
65.79
7,152.00
7,152.00
7,152.00
7,151.00
7,944.00
11,122.00
13,106.00
11,120.00
11,126.00
growth rate 0.0% 10,771.1% 0.0% 0.0% 0.0% 11.1% 40.0% 17.8% -15.2% 0.1%
Cash From OA 445.11
49,914.00
49,943.00
30,251.00
49,415.00
21,624.00
93,420.00
48,711.00
46,128.00
135,601.00
31,239.00
growth rate 11,113.8% 0.1% -39.4% 63.4% -56.2% 332.0% -47.9% -5.3% 194.0% -77.0%
FCF per Share 1.50
0.94
0.68
0.65
0.24
0.90
0.98
1.01
1.26
2.40
growth rate -37.3% -27.7% -4.4% -63.1% 275.0% 8.9% 3.1% 24.8% 90.5%
FCF 39,531.00
39,889.00
28,387.00
17,885.00
39,675.00
8,165.00
81,066.00
35,797.00
32,777.00
124,795.00
23,892.00
growth rate 0.9% -28.8% -37.0% 121.8% -79.4% 892.9% -55.8% -8.4% 280.7% -80.9%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 3,223.53
347,724.00
387,693.00
371,370.00
403,206.00
411,638.00
466,838.00
459,267.00
482,732.00
515,952.00
560,035.00
growth rate 10,687.1% 11.5% -4.2% 8.6% 2.1% 13.4% -1.6% 5.1% 6.9% 8.5%
Op.Income 187.70
25,044.00
42,143.00
23,276.00
36,930.00
52,759.00
82,718.00
61,272.00
82,922.00
54,299.00
59,967.00
growth rate 13,242.7% 68.3% -44.8% 58.7% 42.9% 56.8% -25.9% 35.3% -34.5% 10.4%
IBT 150.21
167.05
34,709.00
33,754.00
39,560.00
47,217.00
84,866.00
65,046.00
83,947.00
77,851.00
82,961.00
growth rate 11.2% 20,677.2% -2.8% 17.2% 19.4% 79.7% -23.4% 29.1% -7.3% 6.6%
Net Income 79.39
10,044.00
20,061.00
15,447.00
24,697.00
28,991.00
53,448.00
48,627.00
40,753.00
56,219.00
56,413.00
growth rate 12,552.0% 99.7% -23.0% 59.9% 17.4% 84.4% -9.0% -16.2% 38.0% 0.4%
EPS 21.72
25.28
50.49
38.88
62.16
78.82
134.53
122.39
102.58
141.50
growth rate 16.4% 99.7% -23.0% 59.9% 26.8% 70.7% -9.0% -16.2% 37.9%
Gross Profit 2,314.16
246,038.00
283,593.00
270,143.00
298,735.00
311,567.00
354,493.00
345,714.00
353,059.00
378,179.00
402,908.00
growth rate 10,531.9% 15.3% -4.7% 10.6% 4.3% 13.8% -2.5% 2.1% 7.1% 6.5%
R&D 523.39
550.56
69,804.00
71,304.00
82,033.00
80,819.00
86,928.00
102,364.00
115,112.00
132,682.00
94,903.00
growth rate 5.2% 12,578.6% 2.2% 15.1% -1.5% 7.6% 17.8% 12.5% 15.3% -28.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 8,306.00
39,266.00
10,656.00
1,739.00
14,614.00
growth rate 372.7% -72.9% -83.7% 740.4%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 155,315.00
176,159.00
156,104.00
151,500.00
168,821.00
growth rate 13.4% -11.4% -3.0% 11.4%
Acct.Payable 65,733.00
48,246.00
50,809.00
46,183.00
58,721.00
growth rate -26.6% 5.3% -9.1% 27.2%
Cur.Assets 442,640.00
449,053.00
467,297.00
499,521.00
557,091.00
growth rate 1.5% 4.1% 6.9% 11.5%
Total Assets 1,276,708.00
1,267,431.00
1,295,913.00
1,308,007.00
1,422,933.00
growth rate -0.7% 2.3% 0.9% 8.8%
Cash 170,918.00
156,468.00
196,340.00
202,984.00
255,443.00
growth rate -8.5% 25.5% 3.4% 25.8%
Inventory 95,221.00
92,788.00
94,323.00
99,021.00
110,114.00
growth rate -2.6% 1.7% 5.0% 11.2%
Cur.Liabilities 256,813.00
260,897.00
271,692.00
278,373.00
320,722.00
growth rate 1.6% 4.1% 2.5% 15.2%
Liabilities 638,014.00
618,749.00
630,142.00
634,438.00
678,519.00
growth rate -3.0% 1.8% 0.7% 7.0%
LT Debt 263,160.00
243,961.00
243,963.00
243,963.00
244,004.00
growth rate -7.3% 0.0% 0.0% 0.0%
Equity 574,042.00
582,308.00
600,786.00
607,888.00
673,010.00
growth rate 1.4% 3.2% 1.2% 10.7%
Common Shares 22,400.00
22,400.00
22,400.00
22,400.00
22,400.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 1,569.00
2,086.00
1,538.00
2,154.00
2,352.00
growth rate 33.0% -26.3% 40.1% 9.2%
Cash Dividends 5,491.00
74.00
5,552.00
9.00
5,488.00
growth rate -98.7% 7,402.7% -99.8% 60,877.8%
Cash From OA -32,805.00
4,597.00
37,269.00
22,178.00
13,189.00
growth rate 100.0% 710.7% -40.5% -40.5%
FCF -34,374.00
2,511.00
35,731.00
20,024.00
10,837.00
growth rate 100.0% 1,323.0% -44.0% -45.9%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 131,196.00
162,534.00
138,342.00
127,963.00
159,876.00
growth rate 23.9% -14.9% -7.5% 24.9%
Op.Income 8,306.00
39,266.00
10,656.00
1,739.00
14,614.00
growth rate 372.7% -72.9% -83.7% 740.4%
IBT 7,957.00
41,309.00
16,317.00
17,378.00
46,610.00
growth rate 419.2% -60.5% 6.5% 168.2%
Net Income 4,802.00
31,648.00
9,909.00
10,054.00
31,108.00
growth rate 559.1% -68.7% 1.5% 209.4%
EPS
growth rate
Gross Profit 92,720.00
124,156.00
97,361.00
88,671.00
113,820.00
growth rate 33.9% -21.6% -8.9% 28.4%
R&D 22,429.00
23,277.00
22,076.00
27,121.00
24,422.00
growth rate 3.8% -5.2% 22.9% -10.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (31.90)

YOY Growth Grade:

E (30.09)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 5.30 5.30 24.87
EPS / Growth 1.55

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 19.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 19.7% 19.7% 19.7%
Future PE 5.30 23.16 23.16
Future EPS 9.30 9.30 9.30
Value Price
MOS %
12.19
48.7%
53.27
549.7%
53.27
549.7%
MOS Price 6.09 26.64 26.64
IRT 3.47 3.47 3.47

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.